[{"address1": "1500 District Avenue", "city": "Burlington", "state": "MA", "zip": "01803", "country": "United States", "phone": "617 600 7373", "website": "https://www.minervaneurosciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Dr. Remy  Luthringer Ph.D.", "age": 62, "title": "Executive Chairman & CEO", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 853582, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geoffrey Robin Race F.C.M.A., M.B.A.", "age": 62, "title": "President", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 628463, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederick W. Ahlholm CPA", "age": 57, "title": "Senior VP, CFO & Secretary", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": 567487, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph  Reilly", "age": 48, "title": "Senior VP & COO", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": 460999, "exercisedValue": 0, "unexercisedValue": 632717}, {"maxAge": 1, "name": "Mr. William B. Boni", "age": 71, "title": "Vice President of Investor Relations & Corporate Communications", "yearBorn": 1952, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Michael  Davidson M.D.", "age": 73, "title": "Chief Medical Officer", "yearBorn": 1950, "fiscalYear": 2022, "totalPay": 657466, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ramana  Kuchibhatla Ph.D.", "title": "Senior VP and Head of Research & Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.58, "open": 2.58, "dayLow": 2.51, "dayHigh": 2.61, "regularMarketPreviousClose": 2.58, "regularMarketOpen": 2.58, "regularMarketDayLow": 2.51, "regularMarketDayHigh": 2.61, "beta": 0.212, "forwardPE": -0.55726874, "volume": 9410, "regularMarketVolume": 9410, "averageVolume": 126986, "averageVolume10days": 25233, "averageDailyVolume10Day": 25233, "marketCap": 17693328, "fiftyTwoWeekLow": 1.5841, "fiftyTwoWeekHigh": 13.49, "fiftyDayAverage": 5.7926, "twoHundredDayAverage": 6.9498005, "currency": "USD", "enterpriseValue": 58587764, "floatShares": 5435555, "sharesOutstanding": 6993410, "sharesShort": 38262, "sharesShortPriorMonth": 23681, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.0055, "heldPercentInsiders": 0.22257, "heldPercentInstitutions": 0.35101002, "shortRatio": 0.14, "shortPercentOfFloat": 0.0094, "impliedSharesOutstanding": 7238310, "bookValue": -4.069, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -30005352, "trailingEps": -4.61, "forwardEps": -4.54, "lastSplitFactor": "1:8", "lastSplitDate": 1655769600, "enterpriseToEbitda": -2.535, "52WeekChange": 0.5665635, "SandP52WeekChange": 0.28136122, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NERV", "underlyingSymbol": "NERV", "shortName": "Minerva Neurosciences, Inc", "longName": "Minerva Neurosciences, Inc.", "firstTradeDateEpochUtc": 1404221400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ceeb0642-b36f-3eda-bb3a-75cdc1b13e8a", "messageBoardId": "finmb_261133065", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.53, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 40912576, "totalCashPerShare": 5.85, "ebitda": -23114134, "totalDebt": 82016824, "quickRatio": 12.248, "currentRatio": 12.574, "returnOnAssets": -0.25806, "freeCashflow": -12688903, "operatingCashflow": -14784732, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-02"}]